JPWO2022104002A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022104002A5 JPWO2022104002A5 JP2023529970A JP2023529970A JPWO2022104002A5 JP WO2022104002 A5 JPWO2022104002 A5 JP WO2022104002A5 JP 2023529970 A JP2023529970 A JP 2023529970A JP 2023529970 A JP2023529970 A JP 2023529970A JP WO2022104002 A5 JPWO2022104002 A5 JP WO2022104002A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- peptide
- cell
- optionally
- mhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113024P | 2020-11-12 | 2020-11-12 | |
| US63/113,024 | 2020-11-12 | ||
| PCT/US2021/059050 WO2022104002A2 (en) | 2020-11-12 | 2021-11-12 | Sars-cov-2 immunodominant peptide constructs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023550094A JP2023550094A (ja) | 2023-11-30 |
| JP2023550094A5 JP2023550094A5 (https=) | 2025-07-22 |
| JPWO2022104002A5 true JPWO2022104002A5 (https=) | 2025-07-22 |
Family
ID=80777877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023529970A Pending JP2023550094A (ja) | 2020-11-12 | 2021-11-12 | Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230398205A1 (https=) |
| EP (1) | EP4244630A4 (https=) |
| JP (1) | JP2023550094A (https=) |
| AU (3) | AU2021323389B1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115785231A (zh) * | 2021-09-10 | 2023-03-14 | 广东菲鹏生物有限公司 | 一种鉴别新冠突变型抗原的抗体、试剂及方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004031210A2 (en) * | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| ES2529736T3 (es) * | 2003-04-10 | 2015-02-25 | Novartis Vaccines And Diagnostics, Inc. | Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS |
| CA2525778A1 (en) * | 2003-05-14 | 2004-12-23 | Siga Technologies, Inc. | T cell epitopes useful in a severe acute respiratory syndrome (sars) virus vaccine and as diagnostic tools and methods for identifying same |
| CA3138174A1 (en) * | 2019-05-21 | 2020-11-26 | David James O'hagan | Yeast-based oral vaccination |
| CN114502191B (zh) * | 2019-08-01 | 2026-04-03 | Acm生物实验室私人有限公司 | 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物 |
| IL296617A (en) * | 2020-03-20 | 2022-11-01 | Biontech Us Inc | Vaccines against the corona virus and methods of use |
| CR20220552A (es) * | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| EP3901261A1 (en) * | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| KR20230006558A (ko) * | 2020-05-06 | 2023-01-10 | 몰리큘라 파트너스 아게 | 신규한 안키린 반복 결합 단백질 및 그의 용도 |
| CN116437951A (zh) * | 2020-05-19 | 2023-07-14 | 磨石生物公司 | Sars-cov-2疫苗 |
| CN111647054B (zh) * | 2020-06-12 | 2021-12-03 | 上海祥耀生物科技有限责任公司 | 一种用于检测新型冠状病毒SARS-CoV-2抗体的试剂及其应用 |
| US20230241205A1 (en) * | 2020-06-17 | 2023-08-03 | Tscan Therapeutics, Inc. | Sars-cov-2 immunodominant peptides and uses thereof |
| WO2022049595A1 (en) * | 2020-09-01 | 2022-03-10 | Helmholtz Zentrum für Infektionsforschung GmbH | Multi-patch vaccines and immunogenic compositions, methods of production and uses thereof |
-
2021
- 2021-11-12 AU AU2021323389A patent/AU2021323389B1/en active Active
- 2021-11-12 JP JP2023529970A patent/JP2023550094A/ja active Pending
- 2021-11-12 US US18/035,369 patent/US20230398205A1/en active Pending
- 2021-11-12 EP EP21892837.2A patent/EP4244630A4/en active Pending
-
2022
- 2022-06-21 AU AU2022204350A patent/AU2022204350B2/en active Active
-
2024
- 2024-08-14 AU AU2024205749A patent/AU2024205749A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12358967B2 (en) | Methods of obtaining tumor-specific T cell receptors | |
| CN110785432B (zh) | Tcr和肽 | |
| Cole et al. | Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen | |
| KR101804078B1 (ko) | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 | |
| JP4607590B2 (ja) | Ｍｈｃクラスｉおよびクラスｉｉ結合ペプチドを検出するための方法およびシステム | |
| JP6718450B2 (ja) | キメラ抗原受容体及びその使用方法 | |
| TW202017940A (zh) | Tcr 配體的高通量肽-mhc親和力篩選方法 | |
| KR20130095186A (ko) | 암, 자가면역 및 감염 질환 면역요법 개발을 위한 자연적으로 가공된 hla-제한 펩티드의 차별 정량법 | |
| CN106132428A (zh) | 用于快速和全面t细胞免疫监测的细胞平台 | |
| JP2007511760A (ja) | Ｍｈｃ結合ペプチドを検出するための溶液ベースの方法 | |
| US7678379B2 (en) | Mycobacterium tuberculosis epitopes and methods of use thereof | |
| Esteban et al. | Directed evolution of soluble single-chain human class II MHC molecules | |
| Hill et al. | Early‐onset myasthenia gravis: A recurring T‐cell epitope in the adult‐specific acetylcholine receptor ε subunit presented by the susceptibility allele HLA‐DR52a | |
| US10024854B2 (en) | Method for detecting and purifying pancreatic beta cells | |
| JP5999703B2 (ja) | ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ | |
| JPWO2022104002A5 (https=) | ||
| Asano et al. | Tumor regression following engineered polyomavirus-specific T cell therapy in immune checkpoint inhibitor-refractory merkel cell carcinoma | |
| JPWO2023086480A5 (https=) | ||
| CN118922435A (zh) | MHC Ib介导的髓鞘特异性免疫抑制作为针对多发性硬化症和MOG抗体疾病的新型治疗方法 | |
| CN117693521A (zh) | 新的肽模拟物及其用途 | |
| JPWO2022221479A5 (https=) | ||
| EP4378533A1 (en) | Patient selection and therapy monitoring for autoimmune disorders | |
| Levin et al. | Availability of autoantigenic epitopes controls phenotype, severity, and penetrance in TCR Tg autoimmune gastritis | |
| US6673350B2 (en) | Tumor associated peptide and uses thereof | |
| CN119930796A (zh) | 一种t细胞受体及其应用 |